• Merck opened a bioprocessing production center in Daejeon, South Korea, with an investment of more than €300 million.
• The 44,500-square-meter facility represents its largest life science investment in Asia-Pacific to date.
• Expanded regional capacity brings critical biologics manufacturing materials closer to Asia-Pacific customers, supporting development through commercial-scale production.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.